Case Reports
doi: 10.1080/08860220601039528.
A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient
Affiliations
- PMID: 17365918
- DOI: 10.1080/08860220601039528
Item in Clipboard
Case Reports
A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient
Ren Fail.
2007.
Free article
Abstract
Renal transplant recipients are susceptible to Kaposi's sarcoma (KS) because of treatment with immunosuppressive drugs. Sirolimus, a new immunosuppressive agent, has been successfully used for immune-suppression in kidney transplant recipients. Several studies have shown the potential role of sirolimus to inhibit progression of KS in kidney-transplant recipients. This report details a kidney-transplant recipient with cutaneous KS who had a complete remission in response to sirolimus therapy.
Similar articles
-
Regression of post-transplant Kaposi's sarcoma using sirolimus.Int J Clin Pract. 2006 Nov;60(11):1509-12. doi: 10.1111/j.1742-1241.2006.00815.x. Int J Clin Pract. 2006. PMID: 16787440
-
Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression.Transpl Int. 2008 Sep;21(9):825-32. doi: 10.1111/j.1432-2277.2008.00697.x. Epub 2008 May 22. Transpl Int. 2008. PMID: 18498314 Review.
-
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.N Engl J Med. 2005 Mar 31;352(13):1317-23. doi: 10.1056/NEJMoa042831. N Engl J Med. 2005. PMID: 15800227 Clinical Trial.
-
Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.Nephrol Dial Transplant. 2007 May;22 Suppl 1:i17-22. doi: 10.1093/ndt/gfm089. Nephrol Dial Transplant. 2007. PMID: 17456614 Review.
-
Sirolimus for visceral and cutaneous Kaposi's sarcoma in a renal-transplant recipient.Clin Exp Nephrol. 2007 Sep;11(3):251-254. doi: 10.1007/s10157-007-0470-y. Epub 2007 Sep 28. Clin Exp Nephrol. 2007. PMID: 17891357
Cited by
-
Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug.PLoS One. 2011 Jan 14;6(1):e14535. doi: 10.1371/journal.pone.0014535. PLoS One. 2011. PMID: 21264294 Free PMC article.
-
Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels.Lasers Surg Med. 2012 Dec;44(10):796-804. doi: 10.1002/lsm.22101. Epub 2012 Dec 4. Lasers Surg Med. 2012. PMID: 23213008 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
